• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    C4 Therapeutics, Inc. - Common Stock (NQ:CCCC)

    3.870 +0.290 (+8.10%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jun 10, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 2,277,297
    Open 3.570
    Bid (Size) 3.760 (800)
    Ask (Size) 3.830 (100)
    Prev. Close 3.580
    Today's Range 3.530 - 3.885
    52wk Range 1.360 - 4.598
    Shares Outstanding 48,797,226
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    C4 Therapeutics to Participate in Upcoming Conferences
    From C4 Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From C4 Therapeutics, Inc.
    Via GlobeNewswire

    Performance

    YTD
    +100.5%
    +100.5%
    1 Month
    +22.1%
    +22.1%
    3 Month
    +29.4%
    +29.4%
    6 Month
    +50.0%
    +50.0%
    1 Year
    +146.5%
    +146.5%

    More News

    Read More
    News headline image
    C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights
    From C4 Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs)
    From C4 Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab (ELREXFIO®) for Relapsed/Refractory Multiple Myeloma
    From C4 Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From C4 Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    C4 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
    From C4 Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    C4 Therapeutics to Participate in Upcoming March Conferences
    From C4 Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    C4 Therapeutics Announces First Patient Dosed in Phase 2 MOMENTUM Trial of Cemsidomide, an Oral IKZF1/3 Degrader, in Combination with Dexamethasone for Relapsed/Refractory Multiple Myeloma
    From C4 Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From C4 Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    C4 Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
    From C4 Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From C4 Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    C4 Therapeutics Outlines Strategic Milestones to Advance Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader and Discovery Strategy Focused on Novel Targets in Clinically Validated Pathways
    From C4 Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    C4 Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference
    From C4 Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    C4 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
    From C4 Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    C4 Therapeutics Announces Pricing of $125 Million Underwritten Offering
    From C4 Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    C4 Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Pfizer for the Combination of Cemsidomide and Elranatamab for the Treatment of Relapsed/Refractory Multiple Myeloma
    From C4 Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Monday's Intraday Session ↗
    Via Benzinga
    News headline image
    Forecasting The Future: 4 Analyst Projections For C4 Therapeutics ↗
    Via Benzinga
    News headline image
    C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting
    From C4 Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Why C4 Therapeutics Stock Crushed the Market on Monday ↗
    Via The Motley Fool
    News headline image
    Here are the top movers in Monday's session. ↗
    Via Chartmill
    News headline image
    12 Health Care Stocks Moving In Monday's Intraday Session ↗
    Via Benzinga
    News headline image
    Which stocks are moving on Monday? ↗
    Via Chartmill

    Frequently Asked Questions

    Is C4 Therapeutics, Inc. - Common Stock publicly traded?
    Yes, C4 Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does C4 Therapeutics, Inc. - Common Stock trade on?
    C4 Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for C4 Therapeutics, Inc. - Common Stock?
    The ticker symbol for C4 Therapeutics, Inc. - Common Stock is CCCC on the Nasdaq Stock Market
    What is the current price of C4 Therapeutics, Inc. - Common Stock?
    The current price of C4 Therapeutics, Inc. - Common Stock is 3.870
    When was C4 Therapeutics, Inc. - Common Stock last traded?
    The last trade of C4 Therapeutics, Inc. - Common Stock was at 06/10/26 04:00 PM ET
    What is the market capitalization of C4 Therapeutics, Inc. - Common Stock?
    The market capitalization of C4 Therapeutics, Inc. - Common Stock is 188.85M
    How many shares of C4 Therapeutics, Inc. - Common Stock are outstanding?
    C4 Therapeutics, Inc. - Common Stock has 189M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.